Olink has created a whitepaper which pulls together three recently published research studies highlighting the importance of linking genetic and protein expression data in the context of disease phenotypes in order to identify new, robust drug targets.
According to Olink, while many drugs are developed based on genomic findings, it’s common for these drugs to fail in the clinical phase due to their inability to provide the expected results for successful treatment. It says that this is because most drugs target proteins, not genes. Although gene transcripts encode the information to make specific proteins, the amount of gene transcript does not always correlate with the amount of protein. On the other hand, focusing on protein levels alone can’t indicate whether any biological changes are a cause or consequence of the disease being studied. This piece of intelligence explains how researchers are finding that a combined approach that integrates genomics with proteomics can overcome these challenges.
Download the whitepaper here